MetaADEDB 2.0 @ LMMD
Caspofungin
(OGUJBRYAAJYXQP-LLXMLGLCSA-N)
Structure
SMILES
CC(=O)O.CC(=O)O.NCCN[C@H]1NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@H](C[C@H]1O)NC(=O)CCCCCCCCC(CC(CC)C)C)[C@H](O)C)C[C@@H](C2)O)[C@@H]([C@H](c1ccc(cc1)O)O)O)[C@@H](CCN)O
Molecular Formula:
C56H96N10O19
Molecular Weight:
1213.420
Log P:
0.2433
Hydrogen Bond Acceptor:
29
Hydrogen Bond Donor:
18
TPSA:
486.63
CAS Number(s):
179463-17-3
Synonym(s)
1.
Caspofungin
2.
Cancidas
3.
Caspofungin Acetate
4.
Caspofungin MSD
5.
L 743,872
6.
L 743872
7.
L-743,872
8.
L-743872
9.
MK 0991
10.
MK-0991
11.
L743,872
12.
L743872
13.
MK0991
External Link(s)
MeSHD000077336
PubChem Compound6850808
ChEBI59900
CHEMBLCHEMBL4297142
KEGGdr:D02501
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 122US FAERS
2SepsisFAERS: 26SIDER
US FAERS
3Septic ShockFAERS: 23SIDER
US FAERS
4Adverse eventFAERS: 15US FAERS
5CandidiasisFAERS: 14US FAERS
6PancreatitisFAERS: 14SIDER
US FAERS
7PneumoniaFAERS: 14SIDER
US FAERS
8OverdoseFAERS: 13
Canada Vigilance: 1		Canada Vigilance
US FAERS
9Respiratory FailureFAERS: 13SIDER
US FAERS
10Bronchopulmonary AspergillosisFAERS: 11US FAERS
11Drug resistanceFAERS: 11US FAERS
12AspergillosisFAERS: 9SIDER
US FAERS
13TachycardiaFAERS: 8SIDER
US FAERS
14Respiratory distressFAERS: 7SIDER
US FAERS
15Febrile NeutropeniaFAERS: 6SIDER
US FAERS
16No adverse eventFAERS: 6US FAERS
17Pathogen resistanceFAERS: 6US FAERS
18Alanine Aminotransferase IncreasedFAERS: 5SIDER
US FAERS
19CholestasisFAERS: 5SIDER
US FAERS
20HepatotoxicityFAERS: 5SIDER
US FAERS
21PancytopeniaFAERS: 5
Canada Vigilance: 1		Canada Vigilance
US FAERS
22Product use in unapproved indicationFAERS: 5US FAERS
23Stevens-Johnson SyndromeFAERS: 5US FAERS
24Therapy non-responderFAERS: 5US FAERS
25Transaminases increasedFAERS: 5US FAERS
26Aspartate Aminotransferase IncreasedFAERS: 4SIDER
US FAERS
27Bacterial sepsisFAERS: 4US FAERS
28ChillsFAERS: 4SIDER
US FAERS
29Drug effect incompleteFAERS: 4US FAERS
30ErythemaFAERS: 4SIDER
US FAERS
31Hepatosplenic candidiasisFAERS: 4US FAERS
32HypotensionFAERS: 4SIDER
US FAERS
33Respiratory tract infection fungalFAERS: 4US FAERS
34TremorFAERS: 4SIDER
US FAERS
35treatment failureFAERS: 4US FAERS
36Blood alkaline phosphatase increasedFAERS: 3SIDER
US FAERS
37Blood creatine phosphokinase increasedFAERS: 3US FAERS
38Cardiac ArrestFAERS: 3SIDER
US FAERS
39Cerebral InfarctionFAERS: 3US FAERS
40Depressed Level of ConsciousnessFAERS: 3US FAERS
41Disease ProgressionFAERS: 3US FAERS
42EosinophiliaFAERS: 3SIDER
US FAERS
43Gamma-Glutamyltransferase IncreasedFAERS: 3SIDER
US FAERS
44HepatitisFAERS: 3SIDER
US FAERS
45HypersensitivityFAERS: 3SIDER
US FAERS
46HypoperfusionFAERS: 3US FAERS
47MalaiseFAERS: 3SIDER
US FAERS
48Medication ErrorFAERS: 3US FAERS
49Product use issueFAERS: 3US FAERS
50RhabdomyolysisFAERS: 3US FAERS
51ShockFAERS: 3
Canada Vigilance: 1		Canada Vigilance
US FAERS
52Systemic mycosisFAERS: 3US FAERS
53UrticariaFAERS: 3SIDER
US FAERS
54Wrong technique in drug usage processFAERS: 3US FAERS
55Accidental exposureFAERS: 2US FAERS
56Acute myocardial infarctionFAERS: 2US FAERS
57AgitationFAERS: 2US FAERS
58Anaphylactic shockFAERS: 2SIDER
US FAERS
59AscitesFAERS: 2SIDER
US FAERS
60Blood pressure fluctuationFAERS: 2US FAERS
61Burning sensationFAERS: 2SIDER
US FAERS
62Candida sepsisFAERS: 2US FAERS
63Carotid artery occlusionFAERS: 2US FAERS
64DehydrationFAERS: 2US FAERS
65Delayed engraftmentFAERS: 2US FAERS
66DisorientationFAERS: 2SIDER
US FAERS
67Drug administration errorFAERS: 2US FAERS
68EcchymosisFAERS: 2US FAERS
69ExtravasationFAERS: 2US FAERS
70General symptomFAERS: 2US FAERS
71Hepatic infection fungalFAERS: 2US FAERS
72Incorrect drug dosage form administeredFAERS: 2US FAERS
73Incorrect route of drug administrationFAERS: 2US FAERS
74Injection Site ReactionFAERS: 2US FAERS
75Injection site extravasationFAERS: 2US FAERS
76LymphomaFAERS: 2US FAERS
77Mental status changesFAERS: 2US FAERS
78Multi-organ disorderFAERS: 2US FAERS
79NauseaFAERS: 2SIDER
US FAERS
80PericarditisFAERS: 2US FAERS
81Prescribed overdoseFAERS: 2US FAERS
82PruritusFAERS: 2SIDER
US FAERS
83Renal abscessFAERS: 2US FAERS
84Renal tubular disorderFAERS: 2US FAERS
85ThrombocytopeniaFAERS: 2
Canada Vigilance: 1		Canada Vigilance
SIDER
US FAERS
86Trichosporon infectionFAERS: 2US FAERS
87ZygomycosisFAERS: 2US FAERS
88Abdominal InfectionFAERS: 1US FAERS
89Abdominal PainFAERS: 1SIDER
US FAERS
90Abdominal tendernessFAERS: 1US FAERS
91Abdominal wound dehiscenceFAERS: 1US FAERS
92Accidental exposure to productFAERS: 1US FAERS
93Accidental overdoseFAERS: 1US FAERS
94AcidosisFAERS: 1
Canada Vigilance: 1		Canada Vigilance
US FAERS
95Acute respiratory failureFAERS: 1US FAERS
96Ammonia increasedFAERS: 1US FAERS
97AtelectasisFAERS: 1US FAERS
98Atrioventricular BlockFAERS: 1US FAERS
99Back PainFAERS: 1SIDER
US FAERS
100Bacteria blood identifiedFAERS: 1US FAERS
101Biliary tract infectionFAERS: 1US FAERS
102BlindnessFAERS: 1US FAERS
103Blood potassium abnormalFAERS: 1US FAERS
104Blood potassium decreasedFAERS: 1SIDER
US FAERS
105BronchiolitisFAERS: 1US FAERS
106Candida serology positiveFAERS: 1US FAERS
107Catheter related complicationFAERS: 1US FAERS
108Cell DeathFAERS: 1US FAERS
109CellulitisFAERS: 1US FAERS
110Cerebellar AtaxiaFAERS: 1US FAERS
111Cerebral aspergillosisFAERS: 1US FAERS
112Cholestatic liver injuryFAERS: 1US FAERS
113Clostridium difficile infectionFAERS: 1US FAERS
114Coagulation test abnormalFAERS: 1US FAERS
115ColitisFAERS: 1US FAERS
116DeliriumFAERS: 1US FAERS
117DermatitisFAERS: 1SIDER
US FAERS
118Diabetes InsipidusFAERS: 1US FAERS
119Disseminated Intravascular CoagulationFAERS: 1US FAERS
120DizzinessFAERS: 1SIDER
US FAERS
121Drug ineffective for unapproved indicationFAERS: 1US FAERS
122Emotional disorderFAERS: 1US FAERS
123EndocarditisFAERS: 1US FAERS
124Enterobacter sepsisFAERS: 1US FAERS
125Enterococcal sepsisFAERS: 1US FAERS
126EnterocolitisFAERS: 1US FAERS
127EpilepsyFAERS: 1US FAERS
128Expired product administeredFAERS: 1US FAERS
129Eyelid irritationFAERS: 1US FAERS
130Fungal test positiveFAERS: 1US FAERS
131General physical health deteriorationFAERS: 1US FAERS
132HeadacheFAERS: 1SIDER
US FAERS
133Histiocytosis haematophagicFAERS: 1US FAERS
134HypoxiaFAERS: 1US FAERS
135Immune Reconstitution Inflammatory SyndromeFAERS: 1US FAERS
136ImmunosuppressionFAERS: 1US FAERS
137Incisional herniaFAERS: 1US FAERS
138IncoherentFAERS: 1US FAERS
139InfarctionFAERS: 1US FAERS
140Infection reactivationFAERS: 1US FAERS
141InfectionFAERS: 1SIDER
US FAERS
142Infusion Site ExtravasationFAERS: 1SIDER
US FAERS
143Infusion site necrosisFAERS: 1US FAERS
144Intestinal PerforationFAERS: 1US FAERS
145Joint swellingFAERS: 1US FAERS
146Klebsiella sepsisFAERS: 1US FAERS
147LymphocytosisFAERS: 1US FAERS
148Maternal exposure during pregnancyFAERS: 1US FAERS
149Mechanical ventilationFAERS: 1US FAERS
150Meningitis aspergillusFAERS: 1US FAERS
151Mixed liver injuryFAERS: 1US FAERS
152MucormycosisFAERS: 1US FAERS
153Mycosis FungoidesFAERS: 1US FAERS
154NecrosisFAERS: 1US FAERS
155NeutropeniaFAERS: 1SIDER
US FAERS
156OsteomyelitisFAERS: 1US FAERS
157Parenteral NutritionFAERS: 1US FAERS
158Partial lung resectionFAERS: 1US FAERS
159Pelvic abscessFAERS: 1US FAERS
160Plasma cells decreasedFAERS: 1US FAERS
161Platelet TransfusionFAERS: 1US FAERS
162PneumothoraxFAERS: 1US FAERS
163Portal HypertensionFAERS: 1US FAERS
164PresyncopeFAERS: 1US FAERS
165Product availability issueFAERS: 1US FAERS
166Product preparation errorFAERS: 1US FAERS
167Product quality issueFAERS: 1US FAERS
168Pulmonary EmbolismFAERS: 1US FAERS
169Respiratory arrestFAERS: 1US FAERS
170Retroperitoneal abscessFAERS: 1US FAERS
171Scedosporium infectionFAERS: 1US FAERS
172SinusitisFAERS: 1US FAERS
173Skin lesionFAERS: 1SIDER
US FAERS
174Splenic infection fungalFAERS: 1US FAERS
175Stenotrophomonas infectionFAERS: 1US FAERS
176Systemic Inflammatory Response SyndromeFAERS: 1US FAERS
177T-Cell LymphomaFAERS: 1US FAERS
178Thermal burnFAERS: 1US FAERS
179ThoracotomyFAERS: 1US FAERS
180TransplantFAERS: 1US FAERS
181Urinary tract infection fungalFAERS: 1US FAERS
182Urinary tract infectionFAERS: 1SIDER
US FAERS
183Ventricular FibrillationFAERS: 1
Canada Vigilance: 1		Canada Vigilance
US FAERS
184VomitingFAERS: 1SIDER
US FAERS
185Abdominal discomfortSIDER
186Acquired Immunodeficiency SyndromeSIDER
187Acute Coronary SyndromeSIDER
188AngioedemaSIDER
189AnorexiaSIDER
190AnxietySIDER
191ArthralgiaSIDER
192AstheniaSIDER
193AtaxiaCanada Vigilance: 1Canada Vigilance
194Atrial FibrillationSIDER
195Bicarbonate decreased serumSIDER
196Bilirubin conjugated increasedSIDER
197Blood albumin decreasedSIDER
198Blood and lymphatic system disordersSIDER
199Blood chloride decreasedSIDER
200Blood chloride increasedSIDER
201Blood creatinine increasedSIDER
202Blood glucose increasedSIDER
203Blood magnesium decreasedSIDER
204Blood phosphorus decreasedSIDER
205Blood phosphorus increasedSIDER
206Blood potassium increasedSIDER
207Blood sodium increasedSIDER
208Blood urea increasedSIDER
209Blood uric acid decreasedSIDER
210Blood urine presentSIDER
211Bone painSIDER
212BradycardiaSIDER
213BronchospasmSIDER
214Carbon dioxide decreasedSIDER
215Catheter site painSIDER
216Central line infectionSIDER
217Chest PainSIDER
218Chest discomfortSIDER
219Complication associated with deviceCanada Vigilance: 1Canada Vigilance
220ConstipationSIDER
221Device occlusionCanada Vigilance: 1Canada Vigilance
222Device related infectionSIDER
223Direct bilirubin increasedSIDER
224DiscomfortSIDER
225DysgeusiaSIDER
226DyspepsiaSIDER
227Electrolyte imbalanceSIDER
228EpistaxisSIDER
229Erythema MultiformeSIDER
230FatigueSIDER
231Feeling abnormalSIDER
232Feeling of body temperature changeSIDER
233FlatulenceSIDER
234Fluid overloadSIDER
235FlushingSIDER
236GastritisSIDER
237Gastrointestinal PainSIDER
238Glucose increasedSIDER
239Hepatic necrosisSIDER
240HepatomegalySIDER
241Immunosuppressant drug level increasedSIDER
242IndurationSIDER
243InfestationSIDER
244Infusion site erythemaSIDER
245Infusion site indurationSIDER
246Infusion site irritationSIDER
247Infusion site painSIDER
248Infusion site phlebitisSIDER
249Infusion site pruritusSIDER
250Infusion site rashSIDER
251Infusion site swellingSIDER
252Infusion site urticariaSIDER
253Injection site erythemaSIDER
254Injection site painSIDER
255Injection site phlebitisSIDER
256LaryngospasmSIDER
257Local reactionSIDER
258Lymphocyte count decreasedSIDER
259Lymphocyte count increasedSIDER
260MalnutritionSIDER
261Metabolic acidosisSIDER
262Musculoskeletal discomfortSIDER
263MyalgiaSIDER
264Myocardial InfarctionSIDER
265Neutrophil count decreasedSIDER
266Ocular icterusSIDER
267PainSIDER
268PalpitationsSIDER
269PetechiaeSIDER
270Pharyngolaryngeal PainSIDER
271PhlebitisSIDER
272Phosphorus lowSIDER
273Potassium lowSIDER
274Protein total decreasedSIDER
275Protein urine presentSIDER
276PrurigoSIDER
277RalesSIDER
278Rash erythematousSIDER
279Sensation of warmthSIDER
280Serum bilirubin increasedSIDER
281Serum calcium decreasedSIDER
282Serum potassium decreasedSIDER
283Serum potassium increasedSIDER
284Serum total protein decreasedSIDER
285SomnolenceSIDER
286StridorSIDER
287SweatingSIDER
288SwellingSIDER
289ThrombocytosisSIDER
290ThrombophlebitisSIDER
291Upset stomachSIDER
292Uric acid increasedSIDER
293Urinary protein increasedSIDER
294VasculitisSIDER
295WheezingSIDER
296White blood cell count decreasedSIDER
297jaundiceSIDER
298nervous system disorderSIDER
299pH urine increasedSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120329

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.